First Indication. In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, the following amounts shall be payable to AstraZeneca from Licensee within [***] ([***]) [***] after the achievement of each of the following milestone events with respect to a Licensed Product in the first indication to reach such milestone, which shall be non-refundable, non- creditable and fully earned upon the achievement of the applicable milestone event: [***] [***] US Dollars (USD $[***]) [***] [***] US Dollars (USD $[***]) [***] [***] [***] US Dollars (USD $[***]) [***] [***] US Dollars (USD$[***]) [***] [***] US Dollars (USD$[***]) Each milestone in this Section 4.3.1 shall be accrued on a Licensed Product-by-Licensed Product basis based on the first achievement of such milestone for the applicable Licensed Product, and shall be paid after the first commercial booking for the Licensed Product.
Appears in 1 contract
Sources: License Agreement (Biohaven Pharmaceutical Holding Co Ltd.)
First Indication. In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, the following amounts shall be payable to AstraZeneca from Licensee within [***] ([***]) [***] after the achievement of each of the following milestone events with respect to a Licensed Product in the first indication to reach such milestone, which shall be non-refundable, non- creditable and fully earned upon the achievement of the applicable milestone event: [***] [***] US Dollars (USD $[***]) [***] [***] US Dollars (USD $[***]) [***] ][***] [***] US Dollars (USD $[***]) [***] [***] US Dollars (USD$[***]) [***] [***] US Dollars (USD$[***]) Each milestone in this Section 4.3.1 shall be accrued on a Licensed Product-by-Licensed Product basis based on the first achievement of such milestone for the applicable Licensed Product, and shall be paid after the first commercial booking for the Licensed Product.
Appears in 1 contract